🇺🇸 AMGN — Amgen Inc.

Healthcare Compra
← Volver

Precio actual

437,23 USD

Máx. histórico

447,03

10 días

Caída desde máximo

-2,19%

Rango 52 semanas

269,77 – 447,03

Variación hoy

-1,55%

Cierre anterior

444,12

Rango de hoy

435,01 – 441,66

Volumen hoy

1.615.172

Información
Nombre completo
Amgen Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
31.500
PER ⓘ
27,17 (puede no estar actualizado)
Dividend yield
2,27% (puede no estar actualizado)
Precio objetivo analistas
389,69 USD (puede no estar actualizado)
Primera cotización
17/06/1983
Precio actualizado
hace 2 días
Sobre la empresa

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Dividendos repartidos Total últimos 12 meses: 9,9400 USD · Yield: 2,27%
Fecha de pago Importe por participación
16/11/2022 1,9400 USD
17/08/2022 1,9400 USD
16/05/2022 1,9400 USD
14/02/2022 1,9400 USD
15/11/2021 1,7600 USD
16/08/2021 1,7600 USD
14/05/2021 1,7600 USD
11/02/2021 1,7600 USD
13/11/2020 1,6000 USD
14/08/2020 1,6000 USD
15/05/2020 1,6000 USD
13/02/2020 1,6000 USD
14/11/2019 1,4500 USD
14/08/2019 1,4500 USD
16/05/2019 1,4500 USD
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
11/02/2020 227,70 229,47 226,80 228,96 +0,68% 1,17% 1.934.500
10/02/2020 228,15 228,96 226,26 227,42 -0,83% 1,18% 2.144.700
07/02/2020 231,41 232,18 227,67 229,33 -0,92% 1,95% 2.295.100
06/02/2020 233,72 233,89 229,34 231,45 -0,21% 1,95% 2.007.500
05/02/2020 223,74 234,64 223,74 231,94 +4,57% 4,87% 3.669.500
04/02/2020 220,77 223,85 220,48 221,81 +2,27% 1,53% 2.765.300
03/02/2020 216,39 219,62 215,56 216,88 +0,38% 1,88% 2.565.400
31/01/2020 218,76 219,08 210,01 216,05 -4,47% 4,15% 5.968.900
30/01/2020 226,00 226,97 223,31 226,15 -0,44% 1,62% 2.581.600
29/01/2020 225,50 228,93 225,00 227,15 +1,03% 1,74% 2.001.100
28/01/2020 223,57 226,70 222,85 224,84 +0,85% 1,72% 2.103.900
27/01/2020 223,68 224,93 221,17 222,95 -1,17% 1,68% 2.843.600
24/01/2020 235,80 235,88 224,50 225,59 -4,02% 4,83% 5.019.900
23/01/2020 237,06 237,06 233,07 235,04 -0,72% 1,68% 2.088.700
22/01/2020 238,75 239,70 235,76 236,75 -0,36% 1,65% 1.998.200
21/01/2020 240,97 242,01 237,26 237,60 -1,61% 1,97% 3.094.200
17/01/2020 242,11 242,14 239,27 241,49 +0,41% 1,19% 2.582.800
16/01/2020 242,18 243,85 239,85 240,50 -0,50% 1,65% 2.085.700
15/01/2020 240,67 242,60 240,05 241,70 +0,71% 1,06% 1.920.700
14/01/2020 235,80 240,68 235,17 240,00 +1,30% 2,34% 2.239.100
13/01/2020 238,26 238,33 234,79 236,92 -0,56% 1,49% 2.004.400
10/01/2020 238,68 240,93 237,61 238,26 -0,28% 1,39% 1.777.600
09/01/2020 239,69 239,69 237,97 238,93 +0,30% 0,72% 1.629.000
08/01/2020 237,93 239,58 236,61 238,22 +0,08% 1,25% 2.214.700
07/01/2020 239,31 240,00 237,59 238,04 -0,94% 1,01% 1.518.900
06/01/2020 237,20 240,45 236,56 240,30 +0,77% 1,64% 1.802.800
03/01/2020 237,16 240,26 236,24 238,47 -0,68% 1,70% 1.879.000
02/01/2020 243,00 243,19 238,98 240,10 -0,40% 1,73% 2.088.000
31/12/2019 240,28 241,46 238,50 241,07 +0,33% 1,23% 1.748.300
30/12/2019 241,40 242,98 239,40 240,27 -0,52% 1,48% 1.454.400